IP Library Granted Patent US 9,523,106
Granted Patent B2
US 9,523,106 · App. 13/557,922 · Granted Dec 20, 2016

Process for the enzymatic production of carnitine from beta-lactones

Inventors: Ellen Klegraf (Brig-Glis, CH); Manuela Avi (Kufstein, AT)
Assignee: LONZA LTD.
C12P13/007C12P7/42C12P7/62C12P41/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,523,106
App. No.
13/557,922
Granted
Dec 20, 2016
Kind
B2
Abstract

Subject of the invention is a process for the production of L-carnitine, wherein a β-lactone, which is a 4-(halomethyl)oxetane-2-one, is converted into L-carnitine, wherein the process comprises an enzymatic conversion of the β-lactone into (R)-4-halo-3-hydroxybutyric acid or (R)-4-halo-3-hydroxybutyric acid ester.

Claims (13)

1. A process for the production of L-carnitine, wherein a β-lactone, which is a 4-(halomethyl)oxetane-2-one, is converted into L-carnitine, wherein the process comprises enzymatic conversion of the β-lactone into (R)-4-halo-3-hydroxybutyric acid, wherein the enzymatic conversion is carried out with a lipase in an aqueous medium, the lipase having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, wherein the enantiomeric purity of the (R)-4-halo-3-hydroxybutyric acid is at least 95% e.e., and conversion of (R)-4-halo-3-hydroxybutyric acid into L-carnitine with trimetylamine.

2. The process of claim 1 , wherein the β-lactone is a racemate.

3. The process of claim 2 , wherein an enantiomeric excess of the (R)-4-halo-3-hydroxybutyric acid is obtained.

4. The process of claim 1 , wherein the enzymatic conversion is carried out in a two phase solution, wherein (R)-4-halo-3-hydroxybutyric acid is enriched in the aqueous phase.

5. The process of claim 1 , wherein after enzymatic conversion, residual β-lactone is removed from the solution.

6. The process of claim 5 , wherein the residual β-lactone is removed by extraction with a solvent.

7. The process of claim 1 , wherein the lipase is from Candida, Pseudomonas, Aspergillus, Bacillus or Thermomyces.

8. The process of claim 1 , wherein the lipase is from Pseudomonas cepacia, Pseudomonas fluorescens , or Candida antarctica.

9. The process of claim 1 , wherein the enzymatic conversion is carried out at a temperature between 0° C. and 50° C., and/or wherein the enzymatic conversion is carried out in an aqueous solution comprising 0.1 to 10 weight % β-lactone.

10. The process of claim 9 , wherein the enzymatic conversion is carried out at a temperature between 20° C. and 40° C., and/or wherein the enzymatic conversion is carried out in aqueous solution comprising 0.1 to 10 weight % β-lactone.

11. The process of claim 1 , in which the β-lactone is synthesized in a preceding step in a [2+2] cycloaddition of ketene and an aldehyde of the formula X-CH2-CHO, wherein x is selected from Cl, Br and I.

12. The process of claim 1 , wherein the total yield of (R)-4-halo-3-hydroxybutyric acid in the enzymatic conversion is between 40% and 50%, based on the total initial amount of β-lactone.

13. The process of claim 1 , wherein the reaction time of the enzymatic conversion of the β-lactone into (R)-4-halo-3-hydroxybutyric acid is less than 10 hours.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2026
From: LONZA LTD, ALSO KNOWN AS LONZA AG
To: CAPSUGEL SWITZERLAND AG
Reel/Frame 073827/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2012
From: KLEGRAF, ELLEN; AVI, MANUELA
To: LONZA LTD.
Reel/Frame 029064/0055 →
Priority Claims (1)
EP 11006163 · Jul 27, 2011 · regional
Continuity (2)
Provisional Application 61512032 · Jul 27, 2011
Related Publication 20130034885A1 · Feb 7, 2013